Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researcher News

DPAG researchers showcased at premier European Society of Cardiology meeting

DPAG scientists across four research groups were highlighted at the major annual European Society of Cardiology basic science conference (FCVB 2022). Congratulations are in order for Dr KC Park on receiving the Young Investigator Award and to Dr Elisabetta Gamen on winning the Moderated Poster Prize.

DPAG Postdoctoral Researcher acknowledged for developmental and cell biology research

Dr Matthew Stower was selected to give an oral presentation of his work and his abstract won the second prize at the Joint Spring Meeting of the British Society for Developmental Biology (BSDB) and the British Society for Cell Biology (BSCB).

The effect of nuclear pH on cardiac gene expression

Research led by Dr Alzbeta Hulikova and Professor Pawel Swietach has, for the first time, described the potential regulation of nuclear acid-base chemistry in neonatal and adult cardiomyocytes, and explained its relevance in the context of heart physiology and pathology.

New insights into little understood regulator of blood sugar levels

A new Novo Nordisk project paper has uncovered the role of ACC1 enzyme in the regulation of glucagon secretion for the first time. This raises the prospect of a potential new therapeutic target in the context of type 2 diabetes and metabolic disorders characterised by hyperglycaemia.

New gene target identified to prevent tumour growth under acidity

A new paper led by Dr Johanna Michl and Professor Pawel Swietach from DPAG’s Swietach Group has identified a new gene that allows cancer cells to survive in the typically acidic microenvironment of a malignant tumour. They have discovered drugs that inhibit the gene in other medical conditions also selectively kill cancer cells at acidic pH, without damaging healthy tissue. This defines a novel strategy for targeting acidic tumour regions.

Latest publications